Merck Reports Positive Late-Stage Trial Results for Keytruda
Merck announced that Keytruda met the primary endpoint in a late-stage clinical trial as a frontline monotherapy for certain endometrial cancer patients. The interim results from its Phase 3 KEYNOTE-C93 trial could enhance the drug's market potential and expand treatment options.
Tickers: $MRK